Great Health Great Fitness
Experimental Drug Lepodisiran Marks Major Breakthrough in Genetic Heart-Disease Risk

A single dose reduces lipoprotein(a) by over 90% in large international trial In a landmark development for cardiovascular medicine, the experimental gene-silencing drug Lepodisiran has delivered dramatic reductions in a genetically-driven heart risk factor known as lipoprotein(a) or “Lp(a)”—a target…









